Every 424B that Citius Oncology, Inc. (CTOR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CTOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTOR filings page.
Citius Oncology, Inc. filed a prospectus supplement updating its registration for 6,818,182 shares of common stock underlying warrants that were exercised at $0.90 per share under a warrant inducement agreement, generating approximately $6.1 million in net proceeds. An additional 272,727 shares remain issuable under placement agent warrants. The company’s Form 10-Q for the quarter ended June 30, 2026 reports $1.5 million in quarterly LYMPHIR product revenue and $7.1 million for the nine months, but also a net loss of $41.1 million and cash of $16.6 million. Citius Oncology discloses substantial doubt about its ability to continue as a going concern beyond November 2026 without additional financing and notes a Nasdaq minimum bid-price deficiency. It entered a term loan facility of up to $25.0 million, with $10.0 million drawn at a minimum interest rate of 12.75%, and incurred significant termination and cancellation fees related to a prior manufacturing contract. The company also expanded its board to nine directors with the appointment of independent director Jonathan Peri and continues the commercial rollout and international access programs for LYMPHIR.
Citius Oncology, Inc. filed a prospectus supplement updating its S-1-based Prospectus after the exercise of 6,818,182 warrants at a reduced exercise price of $0.90 per share under a warrant inducement agreement, generating approximately $6.1 million in net proceeds. The supplement notes that 272,727 placement agent warrants remain outstanding. It also incorporates a Form 8-K and press release describing commercial progress for LYMPHIR, its FDA-approved therapy for relapsed or refractory Stage I–III CTCL.
LYMPHIR is now available in 42 institutions, with new institutional accounts up 78% quarter over quarter and vials ordered up 31%. The initial CTCL market opportunity for LYMPHIR is estimated to exceed $400 million, and management cites near-universal payer coverage and ongoing formulary expansion as key launch indicators.
Citius Oncology, Inc. files a Prospectus Supplement to its Form S-1 registering 6,818,182 shares of common stock underlying warrants and noting 272,727 placement agent’s warrants remain outstanding. The supplement states the 6,818,182 warrants were exercised at a reduced exercise price of $0.90 per share, producing net proceeds to the company of approximately $6.1 million. The supplement attaches a Form 8-K furnishing a press release highlighting Phase 1 investigator-initiated data for LYMPHIR® in combination with pembrolizumab, including a 20.5-month median progression-free survival among patients achieving clinical benefit and a 33% objective response rate in relapsed or refractory endometrial cancer in a small cohort. The supplement must be read with the March 2, 2026 prospectus and updates those disclosures.
Citius Oncology, Inc. files a prospectus supplement dated May 15, 2026 that updates its post-effective S-1 registration and attaches the company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.
The supplement states 6,818,182 shares of common stock underlying previously issued warrants were exercised at a reduced exercise price of $0.90 per share pursuant to a warrant inducement agreement, producing approximately $6.1 million of net proceeds to the company. The supplement also confirms 272,727 placement agent warrants remain outstanding. The company reports 92,981,204 shares outstanding as of May 14, 2026 and discloses cash of $2,632,634 as of March 31, 2026.
Citius Oncology filed a prospectus supplement registering 6,818,182 shares of common stock underlying existing warrants and 272,727 shares underlying the placement agent’s warrants. The company also disclosed a warrant inducement agreement, a Loan and Security Agreement providing up to $25.0 million of term loans and related lender warrants, and a Third Amendment to a promissory note that permits conversion at $0.90 per share. The New Warrants and related lender and placement agent warrants are exercisable only after Stockholder Approval and the filing and effectiveness of a resale registration statement; exercises are subject to beneficial ownership limits and customary adjustment provisions. The company reported aggregate gross proceeds of approximately $11.5 million from the warrant inducement transaction and expects the debt financing to fund operations per the Loan Agreement.
Citius Oncology, Inc. files a prospectus supplement registering 6,818,182 shares of Common Stock underlying the Warrants and 272,727 shares underlying the Placement Agent’s Warrants as part of its Post-Effective Amendment to Registration Statement No. 333-288656. The supplement incorporates Form 8-K disclosures describing positive investigator-initiated Phase 1 topline data for LYMPHIR™ across multiple tumor settings, early U.S. commercial launch traction, and the initial shipment of LYMPHIR to Europe.
The prospectus supplement notes the company’s Common Stock last reported close at $0.92 per share as of May 4, 2026 and includes a Nasdaq notice that the company is below the $1.00 bid-price requirement with a compliance period through October 19, 2026.
Citius Oncology, Inc. is conducting a primary offering of 1,284,404 shares of common stock at $1.09 per share to a single institutional investor, raising gross proceeds of about $1.4 million. After placement agent fees and expenses, the company expects net proceeds of approximately $1.04 million, which it plans to use to support the commercial launch of its FDA‑approved CTCL therapy LYMPHIR and for general working capital needs.
Concurrently, Citius Oncology is issuing in private placements pre‑funded warrants to purchase up to 15,229,358 shares of common stock and an equal number of common warrants, plus additional warrants to buy up to 1,284,404 shares, all outside this prospectus. Following the stock sale, common shares outstanding are expected to be about 84.8 million, assuming no exercise of the new or existing warrants.